Evidence map›Paper›PMID 39460272›Full record

ArticleVaccines2024

A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by

Jérôme Bouvet, Carine Segouffin Cariou, Frantz Oberli, Anne-Laure Guiot, Lionel Cupillard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. FiveMicroorganisms · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jérôme BouvetBoehringer Ingelheim, Centre de Recherche de Saint-Vulbas, Parc Industriel de la Plaine de l'Ain, 805 Allée des Cyprès, 01150 Saint-Vulbas, France.
Carine Segouffin CariouBoehringer Ingelheim, Lyon Porte des Alpes, 99 rue de l'Aviation, 69800 Saint-Priest, France.
Frantz OberliBoehringer Ingelheim, Centre de Recherche de Saint-Vulbas, Parc Industriel de la Plaine de l'Ain, 805 Allée des Cyprès, 01150 Saint-Vulbas, France.
Anne-Laure GuiotCPB-Conseils en Pharmacie et Biologie, 2 Place des Quatre Vierges, 69110 Sainte Foy les Lyon, France.ORCID 0000-0003-3746-0003
Lionel CupillardBoehringer Ingelheim, Lyon Porte des Alpes, 99 rue de l'Aviation, 69800 Saint-Priest, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectiveThe objective was to evaluate the onset and duration of immunity (OOI and DOI) induced by a new licensed quadrivalent antileptospiral vaccine (EURICAN MATERIAL AND

methodsSeven- to ten-week-old puppies received two doses of the vaccine four weeks apart and were challenged with an

resultsThe challenge induced multiple severe clinical signs in controls, leading to the death or euthanasia of 83% of puppies and 57% of adults. In controls, leptospiremia was detected in all dogs, leptospiruria in 67% of puppies and 86% of adults, kidneys tested positive for

conclusionEURICAN

Indexed as

AustralischallengedogLeptospiravaccine

Identifiers

PMID39460272
PMCPMC11511386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.